肯尼亚加里萨和布尼亚拉地区对青蒿素类复方疗法的遵医嘱情况。
Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.
机构信息
The MENTOR Initiative, La Prade, 11150, Villasavary, France.
出版信息
Malar J. 2011 Sep 23;10:281. doi: 10.1186/1475-2875-10-281.
BACKGROUND
Following the development of resistance to anti-malarial mono-therapies, malaria endemic countries in Africa now use artemisinin-based combination therapy (ACT) as recommended first-line treatment for uncomplicated malaria. Patients' adherence to ACT is an important factor to ensure treatment efficacy, as well as to reduce the likelihood of parasite resistance to these drugs. This study reports adherence to a specific ACT, artemether-lumefantrine (AL), under conditions of routine clinical practice in Kenya.
METHOD
The study was undertaken in Garissa and Bunyala districts among outpatients of five government health facilities. Patients treated with AL were visited at home four days after having been prescribed the drug. Respondents (patients ≥ 15 years and caregivers of patients < 15 years) were interviewed using a standardized questionnaire, AL blister packs were physically inspected and the adherence status of patients was then recorded. Multivariate logistic regression modelling was used to determine predictors of adherence.
RESULTS
Of the 918 patients included in the study, 588 (64.1%) were 'probably adherent', 291 (31.7%) were 'definitely non-adherent' and 39 (4.2%) were 'probably non-adherent'. Six factors were found to be significant predictors of adherence: patient knowledge of the ACT dosing regimen (odds ratio (OR) = 1.76; 95% CI = 1.32-2.35), patient age (OR = 1.65; 95% CI = 1.02-1.85), respondent age (OR = 1.37; 95% CI = 1.10-2.48), whether a respondent had seen AL before (OR = 1.46; 95% CI = 1.08-1.98), whether a patient had reported dislikes to AL (OR = 0.62 95% CI = 0.47-0.82) and whether a respondent had waited more than 24 hours to seek treatment (OR = 0.73; 95% CI = 0.54-0.99).
CONCLUSION
Overall, adherence to AL was found to be low in both Garissa and Bunyala districts, with patient knowledge of the AL dosing regimen found to be the strongest predictor of adherence. Interventions aimed at increasing community awareness of the AL dosing regimen, use of child friendly formulations and improving health workers' prescribing practices are likely to ensure higher adherence to AL and eventual treatment success.
背景
随着抗疟单药疗法耐药性的出现,非洲的疟疾流行国家现在将青蒿素为基础的联合疗法(ACT)作为治疗无并发症疟疾的一线推荐治疗方法。患者对 ACT 的依从性是确保治疗效果的一个重要因素,同时也可以降低寄生虫对这些药物产生耐药性的可能性。本研究报告了在肯尼亚常规临床实践条件下,使用特定的 ACT(青蒿琥酯-咯萘啶)的依从性。
方法
该研究在加里萨和邦雅拉地区的五家政府卫生机构进行,对接受青蒿琥酯-咯萘啶治疗的门诊患者在服药后四天进行家访。采用标准化问卷对 15 岁及以上的患者和 15 岁以下患者的照料者进行访谈,检查 AL 药板的实际使用情况,并记录患者的依从性状况。采用多变量逻辑回归模型确定依从性的预测因素。
结果
在纳入研究的 918 名患者中,588 名(64.1%)被认为是“可能依从”,291 名(31.7%)是“肯定不依从”,39 名(4.2%)是“可能不依从”。有 6 个因素被发现是依从性的显著预测因素:患者对 ACT 剂量方案的了解(比值比(OR)=1.76;95%置信区间(CI)=1.32-2.35)、患者年龄(OR=1.65;95%CI=1.02-1.85)、受访者年龄(OR=1.37;95%CI=1.10-2.48)、受访者是否曾见过 AL(OR=1.46;95%CI=1.08-1.98)、患者是否对 AL 有不良反应(OR=0.62;95%CI=0.47-0.82)和受访者是否等待超过 24 小时才寻求治疗(OR=0.73;95%CI=0.54-0.99)。
结论
总体而言,在加里萨和邦雅拉地区,患者对 AL 的依从性均较低,对 AL 剂量方案的了解是依从性的最强预测因素。旨在提高社区对 AL 剂量方案的认识、使用适合儿童的配方和改善卫生工作者的处方实践的干预措施,可能会确保更高的 AL 依从性和最终的治疗成功。